The DETECT Study: chromosomal abnormalities in tubal ectopic pregnancy

  • Research type

    Research Study

  • Full title

    Maternal Serum Cell-free Fetal DNA for Detecting Chromosomal Abnormalities in Tubal Ectopic Pregnancies

  • IRAS ID

    340231

  • Contact name

    Jessica Farren

  • Contact email

    Jessicafarren@nhs.net

  • Sponsor organisation

    University College London Hospital

  • Duration of Study in the UK

    1 years, 2 months, 1 days

  • Research summary

    Background and Importance:

    Tubal ectopic pregnancies (TEPs) occur when a fertilised egg implants in the Fallopian tube instead of the womb, affecting about 1 in 100 pregnancies. TEPs pose serious health risks, including internal bleeding, and cause significant anxiety and stress. Most research on TEPs has focused on cases requiring surgery, leaving a gap in our understanding of smaller TEPs that can often be managed expectantly without surgery. This study aims to use a non-invasive blood test (cffDNA) to detect genetic abnormalities in TEPs, offering insights into their cause without requiring surgery.

    Research Question:

    Can cell-free fetal DNA (cffDNA) testing from maternal blood reliably detect genetic abnormalities in TEPs?

    Relevance and Potential Benefits:

    By determining if genetic abnormalities can be detected non-invasively in expectantly managed TEPs, this study could provide valuable insights into why these pregnancies occur and their likelihood of resolving without intervention. This knowledge could lead to improved management strategies and psychological benefits for affected women.

    Study Design:

    This prospective observational study will recruit participants diagnosed with TEPs on ultrasound scan suitable for expectant management from the Early Pregnancy Unit at University College London Hospital (UCLH). Blood samples will be collected for cffDNA analysis at the same time as routine blood tests for TEPs. If surgery is needed, pregnancy tissue samples will be collected for traditional genetic analysis for comparison.

    Participant Involvement:

    Participants will provide informed consent, have blood samples taken during routine visits, and undergo regular follow-up as part of their standard care. If surgery is needed, pregnancy tissue samples will be sent for genetic testing if they have provided additional consent for this.

    Eligibility:

    Women diagnosed with tubal ectopic pregnancies suitable for expectant management will be recruited.

    Funding:

    Initial feasibility study funded by the Elizabeth Garrett Anderson Hospital Charity.

  • REC name

    London - Surrey Research Ethics Committee

  • REC reference

    25/PR/1521

  • Date of REC Opinion

    17 Dec 2025

  • REC opinion

    Further Information Favourable Opinion